Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination‐free flow cytometry

Takao, Masashi; Takeda, Kazuo

doi:10.1002/cyto.a.21014

Cited by 79 publications

(70 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8B) (On-Chip Biotechnologies Co. Ltd., Tokyo, Japan) 168 . This instrument uses hydrodynamic focusing on a microchip but has several novel capabilities.…”

Section: Integration Of Microfluidics and Microfabrication Into Flmentioning

confidence: 99%

The intersection of flow cytometry with microfluidics and microfabrication

2014

View full text Add to dashboard Cite

A modern flow cytometer can analyze and sort particles on a one by one basis at rates of 50,000 particles per second. Flow cytometers can also measure as many as 17 channels of fluorescence, several angles of scattered light, and other non-optical parameters such as particle impedance. More specialized flow cytometers can provide even greater analysis power, such as single molecule detection, imaging, and full spectral collection, at reduced rates. These capabilities have made flow cytometers an invaluable tool for numerous applications including cellular immunophenotyping, CD4+ T-cell counting, multiplex microsphere analysis, high-throughput screening, and rare cell analysis and sorting. Many bio-analytical techniques have been influenced by the advent of microfluidics as a component in analytical tools and flow cytometry is no exception. Here we detail the functions and uses of a modern flow cytometer, review the recent and historical contributions of microfluidics and microfabricated devices to field of flow cytometry, examine current application areas, and suggest opportunities for the synergistic application of microfabrication approaches to modern flow cytometry.

show abstract

“…8B) (On-Chip Biotechnologies Co. Ltd., Tokyo, Japan) 168 . This instrument uses hydrodynamic focusing on a microchip but has several novel capabilities.…”

Section: Integration Of Microfluidics and Microfabrication Into Flmentioning

confidence: 99%

The intersection of flow cytometry with microfluidics and microfabrication

2014

View full text Add to dashboard Cite

show abstract

“…Circulating tumor cells (CTCs) in peripheral blood from cancer patients, identified in a wide range of malignancies, has already been used as the biomarker for diagnosis and prognosis [59,60]. CTCs have been found in solid tumors, such as prostate and lung cancer [61,62].…”

Section: The Prospect Of Personalized Therapeutics By Ngsmentioning

confidence: 99%

The Development of Cancer Genome Research and its Clinical Opportunity brought by Next Generation Sequencing

Li¹,

Wang²

2012

J Health Med Inform

View full text Add to dashboard Cite

Cancer has been investigated due to its high mortality ever since last century. Although chemotherapy has been traditionally used for cancer patients for a long time, the obvious side effects have prevented its further application. With the progress of DNA sequencing technology, targeted therapy has been developed by affecting targeted molecules in the signaling pathways. It could act as an alternative strategy of cancer therapeutics. In this way, cancer patients could undergo fewer side effects than traditional chemotherapy. In the 21 st century, next generation sequencing (NGS) technologies have emerged to dramatically promote the cancer genome research. Recent researches have shown that the rapid discoveries of mutated cancer genes by NGS are potential to revolutionize cancer therapeutics. In the future, the development of NGS technologies is hopeful to achieve personalized therapeutics in clinic. In this paper, we will first review the previous techniques and achievements of cancer research before the advent of NGS technologies. Then, recent advances in NGS technologies will be highlighted to demonstrate the potential contribution of cancer genomics in the future for prevention, detection and treatment. The Development of Cancer Genome Research and its Clinical Cancer Research before NGS Technologies Traditional cytogenetic studyDuring the cancer research in the past several decades, a variety of techniques were applied to investigate various cancer types. In the earliest stage of cancer research, the chromosome cytogenetic study of cancer cells was the mainstream method. By observing a population of cancer cells, scientists had found that cancer cells appeared to be apparently more unstable than normal cells. Thus, it was hypothesized that the tumor progression might result from acquired genetic variability within the original clone. These researches demonstrated the cytogenetic heterogeneity in human malignancies, suggesting that each patient may require personalized diagnosis and treatment [4].According to the low resolution of cytogenetic study, chromosome was the preferred objective in cancer research. In 1960, the chromosome translocation between chromosomes 9 and 22 was revealed in Chronic Myeloid Leukemia (CML) cells, leading to BCR-ABL fusion gene [5]. Four decades later, the BCR-ABL fusion is regarded as the effective drug target to treat CML patients. In a word, traditional cytogenetic study had demonstrated the cytogenetic heterogeneity of cancer cells and the phenomenon of chromosomal translocation. Moreover, the type and extent of cancer cell aberrations were suggested to be associated with tumorigenesis. Thus, insights had been offered into cancer research that laid the basis for subsequent research and indicated the developmental direction in the future. PCR-based direct sequencing studyBased on the development of cytogenetic techniques in recent years, the resolution of cancer genome research continuously increased. In the 20 th century, it was available to focus on the aberrant geno...

show abstract

“…Strategies using cell-imaging, quantitative RT-PCR (QRT-PCR) [18] and flow cytometric detection [19][20][21] for enumeration and characterization of CTC shave also been employed.…”

Section: Introductionmentioning

confidence: 99%